Maruyama M, Irie T, Yoshida T, Nagahama T, Sugano N, Ebuchi M
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
Gan To Kagaku Ryoho. 1998 Jul;25(9):1439-41.
We studied pharmaco-dynamic changes of intraperitoneal sequential MTX (30 mg)/5-FU (750 mg) therapy in gastric cancer patients with malignant ascites and those who had undergone a gastrectomy. The serum and ascites levels of MTX in patients with malignant ascites decreased much slower than in patients without ascites. In patients with ascites, the serum MTX concentration peaked 8 hours later and then gradually decreased. The ascites MTX level decreased as low as 1/10 2 days after the intraperitoneal administration. The serum and ascites 5-FU levels revealed a minor prolongation of 5-FU concentration in patients with ascites. Gastrectomy did not affect the pharmaco-dynamics of MTX in post-operative patients with sequential intraperitoneal administration of MTX/5-FU on 1, 8 and 15 POD.
我们研究了腹腔序贯甲氨蝶呤（30毫克）/氟尿嘧啶（750毫克）疗法在伴有恶性腹水的胃癌患者以及接受过胃切除术的患者中的药效学变化。伴有恶性腹水的患者血清和腹水中甲氨蝶呤水平下降速度比无腹水患者慢得多。有腹水的患者中，血清甲氨蝶呤浓度在8小时后达到峰值，然后逐渐下降。腹腔给药2天后，腹水甲氨蝶呤水平降至1/10。有腹水患者的血清和腹水氟尿嘧啶水平显示氟尿嘧啶浓度略有延长。胃切除术对术后第1、8和15天序贯腹腔给予甲氨蝶呤/氟尿嘧啶的患者中甲氨蝶呤的药效学没有影响。
